Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AZD9977 in Healthy Volunteers
NCT03435276Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of balcinrenone in heart failure (HF) and chronic kidney disease (CKD) (3 cohorts), sponsored by AstraZeneca. Primary endpoints: Number of subjects with adverse events (AEs) due to AZD9977, Systolic blood pressure [SBP] and 6 more. Started Feb 2018; status: completed.
02
Drugs
balcinrenone
03
Conditions
heart failure (HF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03435276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03435276.